Article
Virological Failure After Switch to Long-Acting Cabotegravir and Rilpivirine Injectable Therapy: An In-depth Analysis.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 19 Jul 2024
van Welzen Berend J, Van Lelyveld Steven F L, Ter Beest Gerjanne, Gisolf Jet H, Geerlings Suzanne E, Prins Jan M, Van Twillert Gitte, Van Nieuwkoop Cees, Van der Valk Marc, Burger David, Wensing Annemarie M J
Abstract excerpt
BACKGROUND: Long-acting (LA) injectable therapy with cabotegravir (CAB) and rilpivirine (RPV) is currently used as maintenance treatment for human immunodeficiency virus type 1, and has a low risk for virological failure (VF). Although the risk is low, the circumstances and impact of VF in the real-world setting merit further evaluation. METHODS: We performed an in-depth clinical, virological, and pharmacokinetic...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.